UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine

Antimicrobial Agents and Chemotherapy, 2012-02, Vol.56 (2), p.751-756

2012

Volltextzugriff (PDF)

Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1

Journal of Virology, 2009-02, Vol.83 (4), p.2029-2033

2009

Volltextzugriff (PDF)

Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.600-607

2011

Volltextzugriff (PDF)

HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug

Antimicrobial Agents and Chemotherapy, 2012-08, Vol.56 (8), p.4257-4267

2012

Volltextzugriff (PDF)

Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.4681-4688

2013

Volltextzugriff (PDF)

Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2007-02, Vol.51 (2), p.604-610

2007

Volltextzugriff (PDF)

Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection

Journal of Virology, 2002-02, Vol.76 (4), p.1753-1761

2002

Volltextzugriff (PDF)

Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection

Antimicrobial Agents and Chemotherapy, 2009-04, Vol.53 (4), p.1670-1672

2009

Volltextzugriff (PDF)

Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine

Antimicrobial Agents and Chemotherapy, 2007-11, Vol.51 (11), p.3861-3869

2007

Volltextzugriff (PDF)

HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.2878-2885

2010

Volltextzugriff (PDF)

Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2

Antimicrobial Agents and Chemotherapy, 2009-02, Vol.53 (2), p.708-715

2009

Volltextzugriff (PDF)

Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT

Antimicrobial Agents and Chemotherapy, 2002-07, Vol.46 (7), p.2087-2094

2002

Volltextzugriff (PDF)

Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations

Antimicrobial Agents and Chemotherapy, 2009-04, Vol.53 (4), p.1683-1685

2009

Volltextzugriff (PDF)

Nucleotide and Amino Acid Polymorphisms at Drug Resistance Sites in Non-B-Subtype Variants of Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 2004-08, Vol.48 (8), p.2993-2998

2004

Volltextzugriff (PDF)

Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture

Antimicrobial Agents and Chemotherapy, 2004-11, Vol.48 (11), p.4189-4194

2004

Volltextzugriff (PDF)

HIV post-treatment controllers have distinct immunological and virological features

Proceedings of the National Academy of Sciences - PNAS, 2023-03, Vol.120 (11), p.e2218960120

2023

Volltextzugriff (PDF)

The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates

Antimicrobial Agents and Chemotherapy, 2003-07, Vol.47 (7), p.2376-2379

2003

Volltextzugriff (PDF)

Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin interventionResearch in context

EBioMedicine, 2023-03, Vol.89, p.104468

2023

Volltextzugriff (PDF)

Pressure of Zidovudine Accelerates the Reversion of Lamivudine Resistance-Conferring M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 2002-07, Vol.46 (7), p.2254-2256

2002

Volltextzugriff (PDF)

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

Journal of virology, 2015-12, Vol.89 (23), p.12002-12013

2015

Volltextzugriff (PDF)

Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV

Cell reports. Medicine, 2024-10, Vol.5 (10), p.101745, Article 101745

2024

Volltextzugriff (PDF)

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase

Antimicrobial agents and chemotherapy, 2014-12, Vol.58 (12), p.7141-7150

2014

Volltextzugriff (PDF)

Variability in the PR and RT Genes of HIV-1 Isolated from Recently Infected Subjects

Antiviral chemistry & chemotherapy, 2004-10, Vol.15 (5), p.255-259

2004

Volltextzugriff (PDF)

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitor

Antimicrobial agents and chemotherapy, 2007, Vol.51 (2), p.604-610

2007

Volltextzugriff (PDF)

A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Quebec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load: e109420

PloS one, 2014-10, Vol.9 (10)

2014

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

KollektionOvid SocietyJournals and Single Titles

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Tagungsberichte
(2)

Sprache

Englisch
(32)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(21)
Humans
(20)
Biological And Medical Sciences
(18)
Antiviral Agents
(17)
Human Immunodeficiency Virus 1
(17)
Medical Sciences
(17)
Pharmacology & Pharmacy
(17)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(16)
Hiv-1
(16)
Microbiology
(16)
Pharmacology. Drug Treatments
(16)
Hiv-1 - Genetics
(15)
Anti-Hiv Agents - Pharmacology
(13)
Hiv-1 - Drug Effects
(13)
Drug Resistance, Viral
(12)
Infectious Diseases
(12)
Anti-Hiv Agents
(11)
Hiv Reverse Transcriptase - Genetics
(11)
Human Viral Diseases
(11)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine

Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1

Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug

Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase

Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors

Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection

Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection

Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine

HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes

Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2

Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT

Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations

Nucleotide and Amino Acid Polymorphisms at Drug Resistance Sites in Non-B-Subtype Variants of Human Immunodeficiency Virus Type 1

Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture

HIV post-treatment controllers have distinct immunological and virological features

The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates

Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin interventionResearch in context

Pressure of Zidovudine Accelerates the Reversion of Lamivudine Resistance-Conferring M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase

Variability in the PR and RT Genes of HIV-1 Isolated from Recently Infected Subjects

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitor

A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Quebec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load: e109420

Aktive Filter

Suchergebnisse filtern